Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+41.4%
5Y CAGR+81.4%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+41.4%/yr
vs +71.2%/yr prior
5Y CAGR
+81.4%/yr
Recent deceleration
Acceleration
-29.8pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
19.7x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $51.59M | +80.6% |
| 2024 | $28.56M | +324.3% |
| 2023 | $6.73M | -63.1% |
| 2022 | $18.25M | +180.4% |
| 2021 | $6.51M | +148.1% |
| 2020 | $2.62M | -38.5% |
| 2019 | $4.27M | +101.1% |
| 2018 | $2.12M | -13.9% |
| 2017 | $2.47M | +235.8% |
| 2016 | $734287.00 | - |